

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/736,250	12/15/2000	Takeshi Nakamura	050212-0278	9013	
7590 04/21/2005			EXAMINER		
McDermott, Will & Emery 600 13th Street, N.W.			YAO, LEI		
Washington, DC 20005-3096			ART UNIT	PAPER NUMBER	
,			1642		
•			DATE MAILED: 04/21/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

Supplemental Notice of Allowability

Application No.	Applicant(s)	
09/736,250	NAKAMURA, TAKESHI	
Examiner	Art Unit	
Lei Yao, Ph.D.	1642	

-					
	Lei Yao, Ph.D.	1642			
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOR (The Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not includ will be mailed in due	ed course. THIS		
1. This communication is responsive to telephone communication.	ation Kelli watson on 4/18/2005.				
2. The allowed claim(s) is/are 1.					
3. The drawings filed on 15 December 2000 are accepted by	the Examiner.				
 Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have Thermal Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 	been received. been received in Application No. <u>09</u> cuments have been received in this i	national stage applica			
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give			OTICE OF		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 					
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 12/15/00 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. Examiner's Stateme 9. Other	(PTO-413), e <u>4/18/2005</u> nent/Comment			

Art Unit: 1642

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted not later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kelli Watson on March 14, 2005.

The application has been amended as follows:

Claim 1 was replaced by the following:

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 1

Claims 6 and 7 were cancelled.

The following is an examiner's statement of reasons for allowance: The prior art does not anticipate or suggest the novel polypeptide of SEQ ID NO:1.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lei Yao, Ph.D. whose telephone number is 571-272-3112. The examiner can normally be reached on 8am-4.30pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Lei Yao, Ph.D.

Examiner Art Unit 1642

KAREN A. CANÉLLA PH.I PRIMARY EXAMINER